Prevention of ASCVD in people with type 2 diabetes:
If the individual does not have established ASCVD, but it at high ASCVD risk,Use
▪️High intensity statin
▪️GLP1 agonist
▪️SGLT2I
Not at high ASCVD risk, use
🔹Moderate or high intensity statin.
#ascvd#statin#sglt2i
ASCVD is defined as a
🔹History of an acute coronary syndrome or myocardial infarction,
🔹Angina,
🔹Coronary heart disease with or without revascularization,
🔹Other arterial revascularization,
🔹Stroke, or
🔹Peripheral artery disease of atherosclerotic in origin
#ascvd
In case of adrenal incidentalomas no further imaging is required, if -
1. Size <4cm,
2. Homogeneous,
3. <10 HU
Ref: European society of Endocrinology guidelines
#adrenal#incidentalomas
INO = Adduction failure ipsilateral to MLF lesion + contralateral abducting nystagmus, Convergence - Preserved Cause: MS, Brain stem Infarct
B/L INO = MS until proven otherwise.
One and Half Syndrome = Only movement left = contralateral abduction
Cause: Pontine infarct, MS
Resmetirom is only indicated in MASLD F2-F3 (At risk MASH)
Not indicated in
🔹Fo-F1 MASLD
🔹Compensated cirrhosis
🔹Decompensated cirrhosis
Ref: ADA guidelines, 2026
#Resmetirom#MASLD#MASH#ADA#FattyLiver
New era of Obesity management. GLP-1–based therapies (especially tirzepatide & semaglutide) dominate across most complications. Drug hierarchy is based on trial evidence, not theoretical weight loss.
#AACE#obesity#diabetes#semaglutide#tirzepatide
Presentation has always been something I truly enjoy — and after a long time, I finally got the chance again! At the Bangladesh Endocrine Society’s Annual International Conference, through an academic contest with 14 endocrinologists, I was delighted to secure first position.